Rosalind Franklin University (RFU) has announced the opening of a new research facility for Tolmar, Inc. at its Innovation and Research Park (IRP) in North Chicago, Illinois. This expansion marks a significant step for Tolmar, a specialty pharmaceutical company renowned for its expertise in long-acting injectable drug delivery systems.
The new Northern Illinois Laboratory will enhance Tolmar’s capacity to develop and commercialize pharmaceutical products, particularly in crucial areas such as urology, oncology, and endocrinology. Founded in 2007, Tolmar has gained international recognition for its innovative approaches in these therapeutic fields. One of its leading products treats advanced prostate cancer and is available in 89 countries.
The establishment of this facility at RFU’s IRP complements the company’s existing operations in Colorado, which house an experienced team of researchers, engineers, and operational staff. This strategic move also strengthens Tolmar’s regional presence, with executive offices and sales personnel located in nearby Buffalo Grove, Illinois.
Dr. Dave Loffredo, Vice President of Innovation at Tolmar, expressed enthusiasm about the expansion. “Tolmar is excited to expand our development capability, now covering both Colorado and Illinois,” he said. “After an exhaustive search, we found a great home at Rosalind Franklin’s IRP. Tolmar scientists are eager to be a part of this dynamic research environment and hope to grow our presence at IRP.”
Dr. Stace Porter, Senior Vice President of Development Operations at Tolmar, highlighted the collaborative potential of the new lab. “At Rosalind Franklin University’s Innovation and Research Park, Tolmar gains world-class research space and the chance to collaborate with leading scientists and advanced research cores,” he noted. The location within Lake County’s vibrant network of life science companies is expected to foster further innovation.
Rosalind Franklin University’s IRP spans 100,000 square feet and is home to several research centers, including the Center for Cancer Cell Biology, Immunology, and Infection. The university is committed to creating an environment that promotes innovative research collaborations. Dr. Joseph DiMario, RFU’s Executive Vice President for Research, welcomed Tolmar and emphasized the potential for accelerated product development through partnerships. “The IRP provides an environment that fosters the kind of intellectual biomedical ‘collisions’ that drive meaningful innovation,” he stated.
Tolmar’s focus on specialty pharmaceuticals encompasses multiple therapeutic areas, positioning the company as a leader in the development and commercialization of advanced drug delivery systems. The new facility at RFU is poised to enhance Tolmar’s research capabilities while contributing to the university’s mission of advancing scientific knowledge.
For more information about Tolmar, visit their official website at www.tolmar.com. To learn more about Rosalind Franklin University, go to rosalindfranklin.edu.
